GENOSS Coronary Stent Clinical Trial

NARecruitingINTERVENTIONAL
Enrollment

850

Participants

Timeline

Start Date

April 24, 2022

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Ischemic Heart Disease
Interventions
DEVICE

Implanatation of Genoss DES sirolimus-eluting coronary system

Percutaneous coronary intervention will proceed as per clinical guidelines, under operator's discretion. Genoss stent will be implanted if the lesion is deemed necessary to be revascularized by stenting

DEVICE

Implanatation of Xience DES everolimus-eluting coronary system

Percutaneous coronary intervention will proceed as per clinical guidelines, under operator's discretion. Xience stent will be implanted if the lesion is deemed necessary to be revascularized by stenting

Trial Locations (1)

135-710

RECRUITING

Cardiac and Vascular Center; Samsung Medical Center, Seoul

All Listed Sponsors
collaborator

Genoss Company Limited, Suwon, Korea

UNKNOWN

lead

Samsung Medical Center

OTHER